首页 > 最新文献

BJU International最新文献

英文 中文
Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer. mri检测Gleason分级组(GG) 2和系统活检检测GG1前列腺癌的复发风险相当。
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-14 DOI: 10.1111/bju.70109
Abderrahim-Oussama Batouche,Eugen Czeizler,Timo-Pekka Lehto,Andrew Erickson,Tolou Shadbahr,Teemu D Laajala,Joona Pohjonen,Tuomas Mirtti,Antti S Rannikko
OBJECTIVETo determine the likelihood of definitive treatment and risk of post-treatment recurrence for patients with Gleason Grade Group (GG) 2 cancer diagnosed using targeted biopsies relative to men with GG1 cancer diagnosed using systematic biopsies.MATERIALS AND METHODSWe performed a retrospective study using a large tertiary centre registry (the HUS Acamedic data lake) to retrieve data on prostate cancer (PCa) diagnosis, treatment, and cancer recurrence. We included patients with either GG1 PCa detected by systematic biopsies (n = 3317) or GG2 PCa detected with targeted biopsies (n = 554) between 1993 and 2019. We assessed the risk of curative treatment and recurrence after treatment. Kaplan-Meier curves were used to estimate treatment- and recurrence-free survival, and Cox proportional hazards regression was used to evaluate the risk of post-treatment recurrence.RESULTSPatients with systematic biopsy-detected GG1 cancer had a significantly longer median time to treatment (31 months) than those with targeted biopsy-detected GG2 cancer (4 months; P < 0.0001). Risk of recurrence after curative treatment was similar in the two groups, with the upper bound of the 95% confidence interval (CI) excluding any significant difference (hazard ratio 1.04, 95% CI 0.75-1.43; P = 0.83).CONCLUSIONMen diagnosed with GG2 PCa based on MRI-targeted biopsy had a similar risk of recurrence after treatment compared to men with GG1 disease diagnosed using systematic biopsy, although they were more likely to undergo curative treatment. These findings suggest that at least a portion of the apparent increase in GG2 diagnoses in the MRI era may reflect reclassification rather than more aggressive disease. Improved risk stratification is needed to identify which men with MRI-era GG2 cancer may be suitable for active surveillance.
目的:相对于采用系统活检诊断为GG1癌的男性,采用靶向活检诊断为Gleason Grade Group (GG) 2癌的患者确定治疗的可能性和治疗后复发的风险。材料和方法我们使用一个大型三级中心登记处(HUS学术数据湖)进行了一项回顾性研究,以检索前列腺癌(PCa)的诊断、治疗和癌症复发的数据。我们纳入了1993年至2019年间通过系统活检检测到GG1型前列腺癌(n = 3317)或通过靶向活检检测到GG2型前列腺癌(n = 554)的患者。我们评估了治愈治疗和治疗后复发的风险。Kaplan-Meier曲线用于估计无治疗和无复发生存期,Cox比例风险回归用于评估治疗后复发风险。结果系统活检检测到GG1癌患者的中位治疗时间(31个月)明显长于靶向活检检测到GG2癌患者(4个月,P < 0.0001)。两组治愈后复发的风险相似,95%置信区间(CI)上界排除任何显著差异(风险比1.04,95% CI 0.75-1.43; P = 0.83)。结论与系统活检诊断为GG1的男性相比,基于mri靶向活检诊断为GG2的男性治疗后复发的风险相似,尽管他们更有可能接受根治性治疗。这些发现表明,在MRI时代GG2诊断的明显增加中,至少有一部分可能反映了重新分类,而不是更具侵袭性的疾病。需要改进风险分层,以确定哪些患有mri时代GG2癌的男性可能适合进行主动监测。
{"title":"Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.","authors":"Abderrahim-Oussama Batouche,Eugen Czeizler,Timo-Pekka Lehto,Andrew Erickson,Tolou Shadbahr,Teemu D Laajala,Joona Pohjonen,Tuomas Mirtti,Antti S Rannikko","doi":"10.1111/bju.70109","DOIUrl":"https://doi.org/10.1111/bju.70109","url":null,"abstract":"OBJECTIVETo determine the likelihood of definitive treatment and risk of post-treatment recurrence for patients with Gleason Grade Group (GG) 2 cancer diagnosed using targeted biopsies relative to men with GG1 cancer diagnosed using systematic biopsies.MATERIALS AND METHODSWe performed a retrospective study using a large tertiary centre registry (the HUS Acamedic data lake) to retrieve data on prostate cancer (PCa) diagnosis, treatment, and cancer recurrence. We included patients with either GG1 PCa detected by systematic biopsies (n = 3317) or GG2 PCa detected with targeted biopsies (n = 554) between 1993 and 2019. We assessed the risk of curative treatment and recurrence after treatment. Kaplan-Meier curves were used to estimate treatment- and recurrence-free survival, and Cox proportional hazards regression was used to evaluate the risk of post-treatment recurrence.RESULTSPatients with systematic biopsy-detected GG1 cancer had a significantly longer median time to treatment (31 months) than those with targeted biopsy-detected GG2 cancer (4 months; P < 0.0001). Risk of recurrence after curative treatment was similar in the two groups, with the upper bound of the 95% confidence interval (CI) excluding any significant difference (hazard ratio 1.04, 95% CI 0.75-1.43; P = 0.83).CONCLUSIONMen diagnosed with GG2 PCa based on MRI-targeted biopsy had a similar risk of recurrence after treatment compared to men with GG1 disease diagnosed using systematic biopsy, although they were more likely to undergo curative treatment. These findings suggest that at least a portion of the apparent increase in GG2 diagnoses in the MRI era may reflect reclassification rather than more aggressive disease. Improved risk stratification is needed to identify which men with MRI-era GG2 cancer may be suitable for active surveillance.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"14 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on 'Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract after spinal cord injury'. 评论“男性是脊髓损伤后逼尿肌压力危及上尿路的危险因素”。
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-14 DOI: 10.1111/bju.70107
Longtu Ma,Rui Lu,Zhilong Dong
{"title":"Comment on 'Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract after spinal cord injury'.","authors":"Longtu Ma,Rui Lu,Zhilong Dong","doi":"10.1111/bju.70107","DOIUrl":"https://doi.org/10.1111/bju.70107","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"57 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts. 扩展Uromonitor®的证据基础:更新八个队列的汇总性能。
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-14 DOI: 10.1111/bju.70113
Matthias May,Anton Kravchuk,Ralph M Wirtz,Thorsten H Ecke,Axel Heidenreich
{"title":"Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts.","authors":"Matthias May,Anton Kravchuk,Ralph M Wirtz,Thorsten H Ecke,Axel Heidenreich","doi":"10.1111/bju.70113","DOIUrl":"https://doi.org/10.1111/bju.70113","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"170 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to: ‘Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts’ 回应:“扩大Uromonitor®的证据基础:更新八个队列的汇总性能”
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-13 DOI: 10.1111/bju.70114
José Rubio‐Briones
{"title":"Response to: ‘Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts’","authors":"José Rubio‐Briones","doi":"10.1111/bju.70114","DOIUrl":"https://doi.org/10.1111/bju.70114","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"6 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145731055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RE: Comment: ‘Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract in patients with spinal cord injury’ 评论:“男性是脊髓损伤患者逼尿肌压力危及上尿路的危险因素”
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-10 DOI: 10.1111/bju.70106
Collene E. Anderson, Veronika Birkhäuser, Martin W. G. Brinkhof, Thomas M. Kessler
{"title":"RE: Comment: ‘Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract in patients with spinal cord injury’","authors":"Collene E. Anderson, Veronika Birkhäuser, Martin W. G. Brinkhof, Thomas M. Kessler","doi":"10.1111/bju.70106","DOIUrl":"https://doi.org/10.1111/bju.70106","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"98 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145711403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
January's reviewers of the month 一月的书评人
IF 4.4 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-10 DOI: 10.1111/bju.70103
<p>Like most journals, BJUI relies on the hard work and dedication of its peer reviewers and we are grateful to them all. Each month the Editorial Team nominates peer reviewers whose reviews have stood out for their quality and timeliness and those selected as the best are highlighted on this page in recognition of their exceptional work.</p><p> <b>Tanja Hüsch</b> </p><p>Her academic focus lies in functional and reconstructive urology, with expertise in neurourology, pelvic floor dysfunction, and urinary incontinence. She has led and contributed to several clinical studies on continence surgery and diagnostic innovation and received several honorary positions at national and international levels.</p><p>Dr. Hüsch's research has been supported by competitive scientific grants and acknowledged with national awards for applied clinical research. She has authored more than 70 peer-reviewed publications and contributed multiple textbook chapters to leading urology references.</p><p>As a Fellow of the European Board of Urology (FEBU), Dr. Tanja Hüsch serves as examiner and mentor, actively promoting academic advancement, education, and gender equity in urology.</p><p> <b>Rustom Manecksha</b> </p><p>He is a consultant urological surgeon with special interests in kidney stone disease and BPH and Clinical Associate Professor of surgery at Trinity College, Dublin. Prof. Manecksha is an active HST trainer and a former National Training Programme Director for Urology. He has an active research and academic profile with over 100 peer-reviewed publications.</p><p> <b>Luis Ribeiro</b> </p><p> <b>Jill Wruble</b> </p><p>Dr Wruble earned her undergraduate degree from Williams College and her medical degree from the New York Institute of Technology College of Osteopathic Medicine. She served in the United States Army Medical Corps, including a tour as a general medical officer at the 43rd MASH in Camp Humphreys, South Korea. She completed her internship and diagnostic radiology residency at Walter Reed Army Medical Center in Washington, D.C., followed by post-doctoral fellowships in body imaging at Georgetown University Medical School and Johns Hopkins Hospital in Baltimore. Dr Wruble retired from the Army with the rank of major. She was the recipient of an honorary doctorate and presented the medical school commencement address at the New York Institute of technology in 2025.</p><p>Dr Wruble serves on the National Cancer Institute's Board for Cancer Screening and Prevention, which critically evaluates medical literature and maintains evidence-based, up-to-date summaries on cancer screening and prevention for healthcare professionals and patients.</p><p>Dr Wruble has worked to enrich radiology teaching in underserved countries. She has contributed substantial time teaching and mentoring residents at Kilimanjaro Christian Medical Center in Moshi, Tanzania. She has also dev
像大多数期刊一样,《北京科技大学学报》依靠同行审稿人的辛勤工作和奉献精神,我们感谢他们所有人。每个月,编辑团队都会提名评审质量和及时性突出的同行审稿人,那些被评为最佳的审稿人将在本页突出显示,以表彰他们的杰出工作。Tanja h sch,主要研究方向为功能和重建泌尿外科,擅长神经病学、盆底功能障碍和尿失禁。她领导并参与了几项关于失禁手术和诊断创新的临床研究,并在国家和国际层面获得了多个荣誉职位。他的研究得到了竞争性科学基金的支持,并获得了国家应用临床研究奖。她撰写了70多篇同行评审的出版物,并为领先的泌尿学参考文献贡献了多个教科书章节。作为欧洲泌尿外科委员会(FEBU)的成员,Tanja h博士作为审查员和导师,积极推动泌尿外科的学术进步、教育和性别平等。Rustom Manecksha他是一名泌尿外科顾问医生,对肾结石疾病和BPH有特殊兴趣,都柏林三一学院临床外科副教授。Manecksha教授是一名活跃的HST培训师和前泌尿外科国家培训项目主任。他拥有活跃的研究和学术形象,发表了100多篇同行评审的出版物。luisribeiro Jill Wruble博士在威廉姆斯学院获得本科学位,并在纽约理工学院骨科医学院获得医学学位。她曾在美国陆军医疗团服役,包括在韩国汉弗莱斯军营的第43医疗团担任一般医疗官。她在华盛顿特区的沃尔特里德陆军医疗中心完成了她的实习和诊断放射学住院医师,随后在乔治城大学医学院和巴尔的摩的约翰霍普金斯医院获得了身体成像博士后奖学金。鲁布尔博士以少校军衔从陆军退役。她获得了荣誉博士学位,并于2025年在纽约理工学院医学院毕业典礼上发表了演讲。Wruble博士在国家癌症研究所癌症筛查和预防委员会任职,该委员会对医学文献进行严格评估,并为医疗保健专业人员和患者维护以证据为基础的最新癌症筛查和预防摘要。Wruble博士致力于丰富服务不足国家的放射学教学。她在坦桑尼亚莫希的乞力马扎罗山基督教医疗中心贡献了大量的时间来教学和指导住院医生。她还为住院医师开发了独特的教学技术,并创立了GlobalMedEd。Inc .是国际放射学培训的非营利组织。它的初始项目是GlobalRadZambia,其中包括赞比亚的第一个放射科住院医师,并利用一群由Wruble招募的美国顶级放射科医生的教学才能。为了减少过度治疗造成的伤害,改善医疗决策,鲁伯博士已经做出了努力。她已经就相关主题发表了两次TEDx演讲,一次是在宾夕法尼亚大学,另一次是在西点军校。在专业工作之余,鲁布尔喜欢与丈夫、五个成年子女和继子女共度时光。她是一个狂热的吉他手和耐力运动爱好者。她还致力于开发讲故事技巧,以提高医学生和住院医师的教育。
{"title":"January's reviewers of the month","authors":"","doi":"10.1111/bju.70103","DOIUrl":"https://doi.org/10.1111/bju.70103","url":null,"abstract":"&lt;p&gt;Like most journals, BJUI relies on the hard work and dedication of its peer reviewers and we are grateful to them all. Each month the Editorial Team nominates peer reviewers whose reviews have stood out for their quality and timeliness and those selected as the best are highlighted on this page in recognition of their exceptional work.&lt;/p&gt;&lt;p&gt;\u0000 &lt;b&gt;Tanja Hüsch&lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;Her academic focus lies in functional and reconstructive urology, with expertise in neurourology, pelvic floor dysfunction, and urinary incontinence. She has led and contributed to several clinical studies on continence surgery and diagnostic innovation and received several honorary positions at national and international levels.&lt;/p&gt;&lt;p&gt;Dr. Hüsch's research has been supported by competitive scientific grants and acknowledged with national awards for applied clinical research. She has authored more than 70 peer-reviewed publications and contributed multiple textbook chapters to leading urology references.&lt;/p&gt;&lt;p&gt;As a Fellow of the European Board of Urology (FEBU), Dr. Tanja Hüsch serves as examiner and mentor, actively promoting academic advancement, education, and gender equity in urology.&lt;/p&gt;&lt;p&gt;\u0000 &lt;b&gt;Rustom Manecksha&lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;He is a consultant urological surgeon with special interests in kidney stone disease and BPH and Clinical Associate Professor of surgery at Trinity College, Dublin. Prof. Manecksha is an active HST trainer and a former National Training Programme Director for Urology. He has an active research and academic profile with over 100 peer-reviewed publications.&lt;/p&gt;&lt;p&gt;\u0000 &lt;b&gt;Luis Ribeiro&lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;\u0000 &lt;b&gt;Jill Wruble&lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;Dr Wruble earned her undergraduate degree from Williams College and her medical degree from the New York Institute of Technology College of Osteopathic Medicine. She served in the United States Army Medical Corps, including a tour as a general medical officer at the 43rd MASH in Camp Humphreys, South Korea. She completed her internship and diagnostic radiology residency at Walter Reed Army Medical Center in Washington, D.C., followed by post-doctoral fellowships in body imaging at Georgetown University Medical School and Johns Hopkins Hospital in Baltimore. Dr Wruble retired from the Army with the rank of major. She was the recipient of an honorary doctorate and presented the medical school commencement address at the New York Institute of technology in 2025.&lt;/p&gt;&lt;p&gt;Dr Wruble serves on the National Cancer Institute's Board for Cancer Screening and Prevention, which critically evaluates medical literature and maintains evidence-based, up-to-date summaries on cancer screening and prevention for healthcare professionals and patients.&lt;/p&gt;&lt;p&gt;Dr Wruble has worked to enrich radiology teaching in underserved countries. She has contributed substantial time teaching and mentoring residents at Kilimanjaro Christian Medical Center in Moshi, Tanzania. She has also dev","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"137 1","pages":"8-9"},"PeriodicalIF":4.4,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.70103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145706280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostate cancer: screening, diagnosis and treatment 前列腺癌:筛查、诊断和治疗
IF 4.4 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-10 DOI: 10.1111/bju.70104
{"title":"Prostate cancer: screening, diagnosis and treatment","authors":"","doi":"10.1111/bju.70104","DOIUrl":"https://doi.org/10.1111/bju.70104","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"137 1","pages":"10-11"},"PeriodicalIF":4.4,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145706284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What are we missing? Identifying clinically significant prostate cancer among patients with low PSA: the utility of the free-to-total PSA ratio. 我们错过了什么?在低PSA患者中识别具有临床意义的前列腺癌:自由-总PSA比值的效用。
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-08 DOI: 10.1111/bju.70110
Daniel Crisafi,Jeffrey Jiang,Damien Bolton,Joseph Ischia,Dixon T S Woon
{"title":"What are we missing? Identifying clinically significant prostate cancer among patients with low PSA: the utility of the free-to-total PSA ratio.","authors":"Daniel Crisafi,Jeffrey Jiang,Damien Bolton,Joseph Ischia,Dixon T S Woon","doi":"10.1111/bju.70110","DOIUrl":"https://doi.org/10.1111/bju.70110","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"136 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urologic chronic pelvic pain syndrome 3-year symptom trajectories: the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Symptom Patterns Study 泌尿系统慢性盆腔疼痛综合征3年症状轨迹:多学科方法研究慢性盆腔疼痛(MAPP)症状模式研究。
IF 4.4 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-02 DOI: 10.1111/bju.70087
Catherine S. Bradley, Mengying You, Wensheng Guo, Niloofar Afari, Priyanka Gupta, Karl J. Kreder, John N. Krieger, H. Henry Lai, Susan K. Lutgendorf, Bruce D. Naliboff, Siobhan Sutcliffe, Frank Tu, David A. Williams, Tara McWilliams, Larissa Rodriguez, J. Richard Landis, for the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network

Objectives

To characterise 3-year pelvic pain and urinary symptom trajectories and to identify baseline factors associated with urologic chronic pelvic pain syndrome (UCPPS) improvement.

Patients and Methods

The Trans-Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Symptom Patterns Study was a multicentre, prospective cohort study of UCPPS, including interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome. Patients completed four weekly run-in assessments, baseline visit, and quarterly visits up to 3 years, providing clinical and patient-reported data. A functional clustering approach, applied separately to Pelvic Pain Severity (PPS) and Urinary Symptom Severity (USS) longitudinal change scores, was used to generate symptom trajectory clusters dichotomised as Group 0 ‘improvers’ vs Groups 1–3 ‘non-improvers’. Logistic regression models explored baseline factors associated with improvement and included run-in period average and baseline scores to adjust for regression to the mean effects.

Results

A total of 545 patients (66% female) were followed for a median (interquartile range) of 34 (23–35) months. Four trajectory clusters were identified for each of PPS and USS, consistent with moderate improvement (Group 0), slight improvement (Group 1), no change (Group 2), and slight worsening (Group 3). In all, 18% and 19% of patients were in the moderately improved PPS and USS groups, respectively, representing 30% of patients overall. Female sex, better sleep, and less opioid use were associated with PPS improvement (Group 0); younger age and baseline cystoscopic treatment were associated with USS improvement (Group 0).

Conclusion

In all, 30% of patients with UCPPS demonstrated improvement in pain and/or urinary symptoms over 3 years. Baseline factors associated with improvement may represent markers of a milder or localised phenotype and/or treatment effects.

目的:描述3年盆腔疼痛和泌尿症状轨迹,并确定与泌尿系统慢性盆腔疼痛综合征(UCPPS)改善相关的基线因素。患者和方法:跨学科方法研究慢性盆腔疼痛(MAPP)症状模式研究是一项多中心、前瞻性队列研究UCPPS,包括间质性膀胱炎/膀胱疼痛综合征和慢性前列腺炎/慢性盆腔疼痛综合征。患者完成了为期3年的4次每周磨合评估、基线访问和季度访问,提供了临床和患者报告的数据。功能聚类方法分别应用于盆腔疼痛严重程度(PPS)和泌尿症状严重程度(USS)纵向变化评分,用于生成症状轨迹聚类,分为0组“改善者”和1-3组“非改善者”。逻辑回归模型探讨了与改善相关的基线因素,并包括磨合期平均值和基线得分,以调整回归到平均效应。结果:共有545例患者(66%为女性)被随访,中位(四分位数范围)为34(23-35)个月。分别为PPS和USS确定了四个轨迹组,分别为中度改善(0组)、轻度改善(1组)、无变化(2组)和轻度恶化(3组)。总的来说,18%和19%的患者分别属于中度改善的PPS组和USS组,占总患者的30%。女性、更好的睡眠和更少的阿片类药物使用与PPS改善相关(0组);年龄较小和基线膀胱镜治疗与USS改善相关(0组)。结论:总的来说,30%的UCPPS患者在3年内表现出疼痛和/或泌尿系统症状的改善。与改善相关的基线因素可能代表轻度或局部表型和/或治疗效果的标志。
{"title":"Urologic chronic pelvic pain syndrome 3-year symptom trajectories: the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Symptom Patterns Study","authors":"Catherine S. Bradley,&nbsp;Mengying You,&nbsp;Wensheng Guo,&nbsp;Niloofar Afari,&nbsp;Priyanka Gupta,&nbsp;Karl J. Kreder,&nbsp;John N. Krieger,&nbsp;H. Henry Lai,&nbsp;Susan K. Lutgendorf,&nbsp;Bruce D. Naliboff,&nbsp;Siobhan Sutcliffe,&nbsp;Frank Tu,&nbsp;David A. Williams,&nbsp;Tara McWilliams,&nbsp;Larissa Rodriguez,&nbsp;J. Richard Landis,&nbsp;for the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network","doi":"10.1111/bju.70087","DOIUrl":"10.1111/bju.70087","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To characterise 3-year pelvic pain and urinary symptom trajectories and to identify baseline factors associated with urologic chronic pelvic pain syndrome (UCPPS) improvement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>The Trans-Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Symptom Patterns Study was a multicentre, prospective cohort study of UCPPS, including interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome. Patients completed four weekly run-in assessments, baseline visit, and quarterly visits up to 3 years, providing clinical and patient-reported data. A functional clustering approach, applied separately to Pelvic Pain Severity (PPS) and Urinary Symptom Severity (USS) longitudinal change scores, was used to generate symptom trajectory clusters dichotomised as Group 0 ‘improvers’ vs Groups 1–3 ‘non-improvers’. Logistic regression models explored baseline factors associated with improvement and included run-in period average and baseline scores to adjust for regression to the mean effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 545 patients (66% female) were followed for a median (interquartile range) of 34 (23–35) months. Four trajectory clusters were identified for each of PPS and USS, consistent with moderate improvement (Group 0), slight improvement (Group 1), no change (Group 2), and slight worsening (Group 3). In all, 18% and 19% of patients were in the moderately improved PPS and USS groups, respectively, representing 30% of patients overall. Female sex, better sleep, and less opioid use were associated with PPS improvement (Group 0); younger age and baseline cystoscopic treatment were associated with USS improvement (Group 0).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In all, 30% of patients with UCPPS demonstrated improvement in pain and/or urinary symptoms over 3 years. Baseline factors associated with improvement may represent markers of a milder or localised phenotype and/or treatment effects.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"137 2","pages":"312-322"},"PeriodicalIF":4.4,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12789841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145653481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transition to a digital perioperative pathway for robot‐assisted radical prostatectomy: impact on patient outcomes and adherence 机器人辅助根治性前列腺切除术向数字化围手术期路径的过渡:对患者预后和依从性的影响
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-02 DOI: 10.1111/bju.70102
Bogdan Adrian Buhas, Alessandro Uleri, Olga Katzendorn, Ambroise Salin, Marine Lesourd, Christophe Almeras, Guillaume Loison, Christophe Tollon, Benjamin Pradère, Jean‐Baptiste Beauval, Bernard Malavaud, Guillaume Ploussard
Objectives To test whether prehabilitation (PreHab), delivered digitally or as digital + on‐site, improves early continence after robot‐assisted radical prostatectomy (RARP) vs no PreHab, and to evaluate implementation by quantifying programme uptake after transitioning from an on‐site programme to a digital pathway. Patients and Methods Two‐centre, high‐volume, non‐randomised before–after consecutive cohort over 3 years ( N = 350; Control = 204; PreHab = 146). PreHab combined pelvic floor muscle training, structured education, and optimisation via a smartphone pathway with or without a 1‐day class. Primary outcome: 6‐week continence (0–1 pad/day). Secondary outcomes: same‐day discharge (SDD), complications (Clavien–Dindo Grade ≥III), 30‐day unplanned visits and readmissions, postoperative physiotherapy, satisfaction (0–10 visual analogue scale), and continence at 6 and 12 months. Group comparisons used chi‐square/Fisher's and Mann–Whitney U ; multivariable logistic regression provided adjusted estimates. Results For the PreHab vs Control cohorts: 6‐week continence 84.2% vs 67.6% ( P = 0.003); SDD 47.3% vs 35.3% ( P = 0.025); high‐grade complications 2.1% vs 7.4% ( P < 0.001); mean (standard deviation) satisfaction score 9.4 (0.7) vs 8.4 (1.3) ( P < 0.001). Readmissions 3.4% vs 7.8% ( P = 0.086) and unplanned visits 3.4% vs 6.4% ( P = 0.218) were not different. Continence remained higher with PreHab at 6 months 97.7% vs 84.3% ( P < 0.001) and 12 months 99.2% vs 93.6% ( P = 0.004). Adjusted analyses showed lower odds of 6‐week incontinence (odds ratio 0.43, 95% confidence interval 0.22–0.85; P = 0.015). Uptake rose from 26.6% (on‐site era) to 48.2% and 68.7% across successive digital periods ( P < 0.001). Effects did not differ by delivery mode. Conclusions Prehabilitation, regardless of delivery mode, improves early continence vs no PreHab without compromising safety; digitisation increased programme uptake, indicating that digital PreHab is an effective and scalable option.
目的:测试预康复(PreHab),以数字化或数字化+现场方式提供,是否能改善机器人辅助根治性前列腺切除术(RARP)后的早期尿失禁,并通过量化从现场方案过渡到数字途径后的方案摄取来评估实施情况。患者和方法:两中心、大容量、非随机、前后连续队列超过3年(N = 350;对照= 204;PreHab = 146)。PreHab结合了盆底肌肉训练、结构化教育和通过智能手机途径进行的优化,有或没有1天的课程。主要终点:6周尿失禁(0-1次/天)。次要结局:同一天出院(SDD)、并发症(Clavien-Dindo分级≥III)、30天计划外就诊和再入院、术后物理治疗、满意度(0-10视觉模拟量表)以及6个月和12个月的尿失禁。组间比较采用卡方/Fisher’s和Mann-Whitney U;多变量逻辑回归提供了调整后的估计。PreHab组与对照组的结果:6周尿失禁84.2% vs 67.6% (P = 0.003);SDD 47.3% vs 35.3% (P = 0.025);高级别并发症2.1% vs 7.4% (P < 0.001);平均(标准差)满意度评分9.4 (0.7)vs 8.4 (1.3) (P < 0.001)。再入院3.4% vs 7.8% (P = 0.086),计划外就诊3.4% vs 6.4% (P = 0.218)无差异。PreHab组6个月的尿失禁率为97.7%比84.3% (P < 0.001), 12个月的尿失禁率为99.2%比93.6% (P = 0.004)。校正分析显示6周尿失禁的几率较低(优势比0.43,95%可信区间0.22-0.85;P = 0.015)。在连续的数字时代,采用率从26.6%(现场时代)上升到48.2%和68.7% (P < 0.001)。效果没有因递送方式而异。结论:与不使用预康复相比,无论哪种交付方式,预康复在不影响安全性的情况下都能改善早期尿失禁;数字化增加了项目的吸收,表明数字化PreHab是一种有效且可扩展的选择。
{"title":"Transition to a digital perioperative pathway for robot‐assisted radical prostatectomy: impact on patient outcomes and adherence","authors":"Bogdan Adrian Buhas, Alessandro Uleri, Olga Katzendorn, Ambroise Salin, Marine Lesourd, Christophe Almeras, Guillaume Loison, Christophe Tollon, Benjamin Pradère, Jean‐Baptiste Beauval, Bernard Malavaud, Guillaume Ploussard","doi":"10.1111/bju.70102","DOIUrl":"https://doi.org/10.1111/bju.70102","url":null,"abstract":"Objectives To test whether prehabilitation (PreHab), delivered digitally or as digital + on‐site, improves early continence after robot‐assisted radical prostatectomy (RARP) vs no PreHab, and to evaluate implementation by quantifying programme uptake after transitioning from an on‐site programme to a digital pathway. Patients and Methods Two‐centre, high‐volume, non‐randomised before–after consecutive cohort over 3 years ( <jats:italic>N</jats:italic> = 350; Control = 204; PreHab = 146). PreHab combined pelvic floor muscle training, structured education, and optimisation via a smartphone pathway with or without a 1‐day class. Primary outcome: 6‐week continence (0–1 pad/day). Secondary outcomes: same‐day discharge (SDD), complications (Clavien–Dindo Grade ≥III), 30‐day unplanned visits and readmissions, postoperative physiotherapy, satisfaction (0–10 visual analogue scale), and continence at 6 and 12 months. Group comparisons used chi‐square/Fisher's and Mann–Whitney <jats:italic>U</jats:italic> ; multivariable logistic regression provided adjusted estimates. Results For the PreHab vs Control cohorts: 6‐week continence 84.2% vs 67.6% ( <jats:italic>P</jats:italic> = 0.003); SDD 47.3% vs 35.3% ( <jats:italic>P</jats:italic> = 0.025); high‐grade complications 2.1% vs 7.4% ( <jats:italic>P</jats:italic> &lt; 0.001); mean (standard deviation) satisfaction score 9.4 (0.7) vs 8.4 (1.3) ( <jats:italic>P</jats:italic> &lt; 0.001). Readmissions 3.4% vs 7.8% ( <jats:italic>P</jats:italic> = 0.086) and unplanned visits 3.4% vs 6.4% ( <jats:italic>P</jats:italic> = 0.218) were not different. Continence remained higher with PreHab at 6 months 97.7% vs 84.3% ( <jats:italic>P</jats:italic> &lt; 0.001) and 12 months 99.2% vs 93.6% ( <jats:italic>P</jats:italic> = 0.004). Adjusted analyses showed lower odds of 6‐week incontinence (odds ratio 0.43, 95% confidence interval 0.22–0.85; <jats:italic>P</jats:italic> = 0.015). Uptake rose from 26.6% (on‐site era) to 48.2% and 68.7% across successive digital periods ( <jats:italic>P</jats:italic> &lt; 0.001). Effects did not differ by delivery mode. Conclusions Prehabilitation, regardless of delivery mode, improves early continence vs no PreHab without compromising safety; digitisation increased programme uptake, indicating that digital PreHab is an effective and scalable option.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"5 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145651143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BJU International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1